Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Understanding resistance to combination chemotherapy
Justin R. Pritchard
, Douglas A. Lauffenburger
, Michael T. Hemann
Biomedical Engineering
Huck Institutes of the Life Sciences
Penn State Cancer Institute
Cancer Institute, Mechanisms of Carcinogenesis
Research output
:
Contribution to journal
›
Review article
›
peer-review
91
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Understanding resistance to combination chemotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Combination Therapy
100%
Combination Chemotherapy
100%
Resistance Mechanisms
66%
Drug Regimen
66%
Clinical Application
33%
Mechanism of Action
33%
Cancer Cells
33%
Drug Development
33%
Maximum Tolerated Dose
33%
Drug Resistance
33%
New Therapeutics
33%
Targeted Therapy
33%
Anticancer
33%
Combination Regimen
33%
Clinical Investigator
33%
Drug Combination
33%
Multiple Drugs
33%
Multidrug Regimen
33%
Rational Development
33%
Network Biology
33%
Systems Network
33%
Emerging Approaches
33%
Therapeutic Combinations
33%
Combinatorial Regimens
33%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Chemotherapy
100%
Combination Therapy
100%
Combination Drug
66%
Drug Development
33%
Maximum Tolerated Dose
33%
Drug Resistance
33%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Genomics
100%
Drug Resistance
50%
Anticancer
50%
Maximum Tolerated Dose
50%
Cell Killing
50%
Immunology and Microbiology
Cancer Cell
100%
Drug Resistance
50%
Cell Killing
50%
Maximum Tolerated Dose
50%